Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CBX-663 |
| Synonyms | |
| Therapy Description |
CBX-663 is a T-cell receptor (TCR) mimetic T-cell engager comprising a CD3-binding domain and two TCR domains targeting TERT and HLA-A*02:01, which potentially induces T cell-mediated cytotoxicity and inhibits tumor growth (Cancer Res (2026) 86 (7_Supplement): 1635). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CBX-663 | CBX663|CBX 663 | CBX-663 is a T-cell receptor (TCR) mimetic T-cell engager comprising a CD3-binding domain and two TCR domains targeting TERT and HLA-A*02:01, which potentially induces T cell-mediated cytotoxicity and inhibits tumor growth (Cancer Res (2026) 86 (7_Supplement): 1635). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07779798 | Phase I | CBX-663 | A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma. (TelOscope) | Not yet recruiting | USA | 0 |